These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20213911)

  • 1. [Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].
    Shvarts PG; Kadykov AS; Shvedkov VV; Timerbaeva SL; Polevaia EV; Mulach AN
    Urologiia; 2009; (5):24-9. PubMed ID: 20213911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity].
    Mazo EB; Krivoborodov GG; Shkol'nikov ME; Babanina GA; Kozyrev SV; Korshunov ES
    Urologiia; 2005; (4):56-9. PubMed ID: 16158750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose trospium chloride in therapy of detrusor hyperreflexia].
    Madersbacher H; Stöhrer M; Richter R; Giannetti BM; Mürtz G
    Urologe A; 1991 Jul; 30(4):260-3. PubMed ID: 1926674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
    Mazo EB; Babanina GA
    Urologiia; 2007; (3):15-9. PubMed ID: 17722614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.
    Horstmann M; Schaefer T; Aguilar Y; Stenzl A; Sievert KD
    Neurourol Urodyn; 2006; 25(5):441-5. PubMed ID: 16847942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily.
    Fröhlich G; Bulitta M; Strösser W
    Int J Clin Pharmacol Ther; 2002 Jul; 40(7):295-303. PubMed ID: 12139206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trospium chloride in combined treatment of females with genital prolapse and overactive urinary bladder].
    Shkol'nikov Me; Mazo EB; Krivoborodov GG; Dobrokhotova IuE; Kaĭfadzhan MM; Fandeeva LV; Nurullin RF; Zhdanova MS
    Urologiia; 2008; (5):16-9. PubMed ID: 19069489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?
    Menarini M; Del Popolo G; Di Benedetto P; Haselmann J; Bödeker RH; Schwantes U; Madersbacher H;
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):623-32. PubMed ID: 17190372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release trospium chloride improves quality of life in overactive bladder.
    Dmochowski RR; Rosenberg MT; Zinner NR; Staskin DR; Sand PK
    Value Health; 2010; 13(2):251-7. PubMed ID: 19818062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release.
    Chancellor MB; Oefelein MG; Vasavada S
    Neurourol Urodyn; 2010 Apr; 29(4):551-4. PubMed ID: 19634167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term safety and efficacy of trospium chloride for the treatment of neurogenic overactive bladder due to Parkinson's disease is there an effect on cognitive status?].
    Korshunova ES; Andreev MN; Korshunov MN; Pyatnitskaya TM; Korshunov DM; Darenkov SP; Suponeva NA
    Urologiia; 2022 Dec; (6):71-77. PubMed ID: 36625617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Overactive bladder as a mask of chronic prostatitis].
    Kul'chavenia EV; Brizhatiuk EV; Breusov AA
    Urologiia; 2012; (6):43-4, 46. PubMed ID: 23379238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment.
    Rudy D; Cline K; Harris R; Goldberg K; Dmochowski R
    BJU Int; 2006 Mar; 97(3):540-6. PubMed ID: 16469022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.